Medical giant Amersham surges after Â£5bn takeover approach
Thursday 09 October 2003
Amersham, the medical technology company which grew out of the Government's atomic energy programme, has attracted a £5bn takeover approach.
The company was forced to admit yesterday that it is in early talks with a mystery bidder, sparking a day of intense speculation over the identity of the predator and sending Amersham shares up 16 per cent.
Analysts said a US firm was the most likely bidder, although Roche, the Swiss pharmaceuticals group, was also in the frame. The diverse nature of the Amersham business meant there was little agreement, even on which industry the approach may come from.
Amersham, led by Sir William Castell, the chief executive, confirmed the approach after takeover speculation pushed its shares up in early trading. The stock had been briefly suspended on the Oslo bourse, which said it was investigating insider trading.
The company said: "Amersham announces that it has received an approach which may or may not lead to an offer for the company as a whole. No agreement has been reached and a further announcement will be made as appropriate."
Amersham shares initially leapt by a quarter as hedge funds scrambled to close short positions, and the stock settled up 89.5p at 641p, valuing the company at £4.5bn.
Sir William has grown Amersham through a string of mergers to become the market leader in diagnostic imaging, making chemicals to enhance the images from x-rays and other body scans. This historic business grew out of a wartime research centre examining uses for radium ore, then used to produce luminous paint for ships and airplanes, and the company became, in 1983, the first to be privatised by Margaret Thatcher's government.
Amersham's newer businesses are protein separations, used in drug research and manufacture, and discovery systems, which makes laboratory equipment for medical research.
Potential bidders mentioned during yesterday's frenzied trading session - when eight times the usual number of Amersham shares were traded - included General Electric, the US conglomerate which already has a product development agreement with Amersham.
Max Herrmann, an analyst at ING Financial Markets, said the company would fit with Roche's diagnostics and drug research interests, and also with the diverse hospital supplies business being expanded by Johnson & Johnson, the US medical giant.
But others believed a perceived undervaluation of the smallest business - the troubled discovery systems division - might be behind the approach.
Mark Brewer of Dresdner Kleinwort Wasserstein said the discovery systems industry was in need of consolidation and this was the Amersham division with the most scope for improvement in margins.
He said: "Any bidder would ultimately break up the company, because none of the potential acquirers has a presence in all three of Amersham's markets. But I am not sure it has to be taken over to achieve value for shareholders, as a break-up is something the company itself could do."
Sir William, already one of the FTSE 100's best paid chief executives with a package worth £1.1m last year, would net £1.8m for his shares in the company if a bid went through at close to the current share price. The 56-year-old former Wellcome executive agreed last year to stay on "for the foreseeable future" as chief executive, prompting a potential successor, John Pafield, to leave the business. Friends say Sir William would like to go out on a deal.
New UK station Russia Today gives a very bizarre view of Britain
By performing as African Americans or Indians, white people get to play act a kind of 'imaginary liberation', writes Michael Mark Cohen
New essay by JK Rowling went live on Pottermore site this morning
Top Gear presenter is no stranger to foot-in-mouth controversy
- 1 'Nasa Confirms Six Days of Darkness in December': No, they don't - it's a hoax
- 2 Canadian actor punched in face after 'Islamophobia' experiment goes wrong in wake of Ottawa shooting
- 3 Topshop at centre of row over body image as 'shocking' skinny mannequin photo goes viral
- 4 If you think Russell Brand’s new book is confused, you should read what his critics have to say about it
- 5 Kentucky gang rape: 15-year-old boy left in critical condition after sexual attack by group at party
'Nasa Confirms Six Days of Darkness in December': No, they don't - it's a hoax
Canadian actor punched in face after 'Islamophobia' experiment goes wrong in wake of Ottawa shooting
Halloween 2014: From the Screaming Man of Pluckley to the 'White Lady' of the Tower of London - Britain's 20 most haunted places
Russian politician says Apple CEO Tim Cook should be 'banned' from country after coming out as gay
Kentucky gang rape: 15-year-old boy left in critical condition after sexual attack by group at party
Pope Francis declares evolution and Big Bang theory are real and God is not 'a magician with a magic wand'
Huge surge in Ukip support after EU funding row, according to new poll
Ukip ‘exploiting grooming scandal’ to secure party’s first police chief
Nigel Farage: 'There’s nothing wrong with white people blacking up'
Maureen Lipman says 'she can't vote Labour while Ed Miliband is leader'
Muslims, immigration and teenage pregnancy: British people are ignorant about almost everything
iJobs Money & Business
£18000 - £23000 per annum + Comission: SThree: SThree, International Recruitme...
£20000 - £25000 per annum + OTE £35K: SThree: We consistently strive to be the...
£20000 - £23250 Per Annum pro rata: Clearwater People Solutions Ltd: Pro rata ...
£40 - 48k + Benefits: Guru Careers: We are seeking a Marketing Manager to join...